drugset
Drugs / (-)-Epicatechin
last change Apr 2026 re-read 3 minutes ago

(-)-Epicatechin

also known as EPI
Developed for
Becker muscular dystrophy · prediabetes syndrome · Duchenne muscular dystrophy · Friedreich ataxia · pulmonary arterial hypertension
Investigated by
Cardero Therapeutics, Inc. · Craig McDonald, MD · National Institutes of Health (NIH) · National Center for Complementary and Integrative Health (NCCIH) · San Diego Veterans Healthcare System · University of California, San Diego
+6 more · Veterans Medical Research Foundation · Epirium Bio Inc. · National Institute on Aging (NIA) · Ralitza Gavrilova · University of Alabama at Birmingham · University of California, San Francisco

Trials 9

today NCT07161726 · Ph 1/2 NCT04386304 · Ph 1 NCT03236662 · Ph 2 NCT02964377 · Ph 1/2 NCT02660112 · Ph 2 NCT02656212 · Ph 1 NCT02330276 · Ph 1 NCT01880866 · Ph 1 NCT01856868 · Ph 1/2
2013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT04386304 Jul 2020 → Mar 2022 Becker muscular dystrophy Epirium Bio Inc. Completed No outcome recorded
Phase 1 NCT02656212 Sep 2015 → Apr 2016 prediabetes syndrome Veterans Medical Research Foundation Completed No outcome recorded
Phase 1 NCT02330276 Sep 2014 → Aug 2015 prediabetes syndrome Veterans Medical Research Foundation Completed No outcome recorded
Phase 1 NCT01880866 Jul 2013 → Jan 2014 pulmonary arterial hypertension University of California, San Francisco Withdrawn No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07161726 Apr 2026 → Dec 2027 expected — University of Alabama at Birmingham Recruiting No outcome recorded
Phase 1/2 NCT02964377 Nov 2016 → Jul 2018 Duchenne muscular dystrophy Craig McDonald, MD Completed No outcome recorded
Phase 1/2 NCT01856868 May 2013 → Sep 2018 Becker muscular dystrophy Craig McDonald, MD Completed No outcome recorded
Phase 22 trials · 1 missed
Phase 2 NCT03236662 Nov 2016 → Nov 2017 Becker muscular dystrophy Craig McDonald, MD Completed No outcome recorded
Phase 2 NCT02660112 Sep 2016 → Dec 2018 Friedreich ataxia Ralitza Gavrilova Completed Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as (+)-epicatechin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02330276 ↗
8

NCT03236662 ↗

NCT02964377 ↗

NCT07161726 ↗

NCT04386304 ↗

NCT02656212 ↗

NCT01856868 ↗

NCT02660112 ↗

NCT01880866 ↗
Known as EPI “BACKGROUND: (+)-Epicatechin (EPI) induces mitochondrial biogenesis and antioxidant metabolism in muscle fibers and neurons.” PMID 32677106 ↗ Aug 2020
Modality Small molecule “(+)-Epicatechin is a synthetic flavanol” NCT04386304 ↗
Route Oral “100mg/day orally for 8 weeks.” NCT01856868 ↗